Ascelia Pharma AB Email Format
Pharmaceutical ManufacturingSkåne, Sweden11-50 Employees
Ascelia Pharma AB is a Swedish biotech company focused on orphan oncology treatments. Based in Malmö, it develops and commercializes novel drugs with defined development and market pathways, targeting unmet medical needs. The company has two drug candidates in clinical development: Orviglance and Oncoral, with Orviglance designed as an oral contrast agent to improve detection of focal liver lesions in patients with reduced kidney function and having FDA Orphan Drug Designation while progressing in Phase 3. Oncoral is an oral irinotecan tablet in development for gastric cancer, offering potential safety and convenience advantages over traditional IV infusions, with Phase 2 development in planning after Phase 1. The firm, based in Malmö and listed on Nasdaq Stockholm, has publicly shared progress including abstracts accepted for presentation at ESGAR 2026.